solute carrier family 22 member 10 (gene/pseudogene)Genealiases: OAT5 · hOAT5
Q-omics provides the consensus-scored SLC22A10 profile across patient tissues and cancer cell-line models. SLC22A10 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, SLC22A10 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, SLC22A10 RNA expression shows 10,283 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, LIHC, and GBM as cancer lineages where SLC22A10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC22A10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC22A10 survival associations across molecular data types. SLC22A10 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC22A10 RNA expression–survival associations across cancer types. High SLC22A10 expression shows unfavorable associations in SCLC and COAD, but favorable associations in BRCA, BLCA, LUAD and READ. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for SLC22A10 RNA expression.
This table summarizes SLC22A10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC22A10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC22A10 shows lower tumor expression in LIHC, LUAD, CHOL and LUSC and higher tumor expression in PRAD and KICH. The LIHC box plot shows higher SLC22A10 RNA expression in normal versus tumor tissue (log2 FC = −2.496, t-test p < 0.001).
This table shows molecular features associated with SLC22A10 in patient tissues and cancer cell lines. In patient samples, SLC22A10 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC22A10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
